Signet Therapeutics

Signet Therapeutics is an innovative cancer targeted drug R&D company based on disease models and AI. Founded in late 2020, the company originated on the campus of Harvard University. Its core team comprises outstanding talents from academia—including Harvard University, the Massachusetts Institute of Technology (MIT), and the Chinese Academy of Sciences—as well as from the pharmaceutical industry. Headquartered in Shenzhen, Signet Therapeutics also maintains a branch in Boston, USA. The Chinese name “Xige” is not only a phonetic translation of “Signet,” but also embodies the vision of “harboring hope and pursuing knowledge through rigorous inquiry.” Through the team’s professionalism, cutting-edge expertise, and relentless pursuit of excellence, Signet Therapeutics strives to instill hope in cancer patients who currently have no treatment options. The company is dedicated to transforming highly lethal malignant cancers into manageable chronic diseases through precise targeted therapies.